Shares of diversified healthcare company CVS Health (NYSE:CVS)
jumped 2.9% in the afternoon session after broad positive sentiment in the healthcare sector was supported by a bullish analyst outlook.
Each stock in this article is trading near its 52-week high.
These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Oscar Health (NYSE:OSCR) and the best and worst performers in the health insurance providers industry.
Shares of diversified healthcare company CVS Health (NYSE:CVS)
fell 4.8% in the afternoon session after two Republican congressmen launched an investigation into the company over concerns it may have violated the HIPAA privacy law.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
As the financial world braces for the highly anticipated Federal Open Market Committee (FOMC) meeting on September 16-17, 2025, market participants are largely anticipating a significant shift in monetary policy. The strong likelihood of a 25-basis-point interest rate cut by the Federal Reserve is now a central focus, promising to
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at health insurance providers stocks, starting with Clover Health (NASDAQ:CLOV).
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at health insurance providers stocks, starting with Humana (NYSE:HUM).
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Elevance Health (NYSE:ELV) and its peers.
